newsfilter
← Latest News
ACCESS Newswire·

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company , and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals